Swiss pharmaceutical firm Helsinn Healthcare SA on said it has settled patent litigations relating to its antinausea injection Aloxi with Dr. Reddy's Laboratories Ltd which will allow Dr. Reddy's to market the generic version of Aloxi in the US on 30 September 2018 or earlier under certain circumstances. The terms of the settlement agreement were not disclosed.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.









